Immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer and other solid tumors: is it truly disease-agnostic?
Notably, the authors included 27 cancer types in their cohort, where the most common cancers were endometrial (n=49), gastric (n=24), cholangiocarcinoma (n=22), pancreatic (n=22) and small intestine (n=19). Overall, the studies above clearly suggest that MMR-D in solid tumors is a predictor of respo...
Saved in:
Published in | Colorectal cancer Vol. 9; no. 4 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
London
Future Medicine Ltd
19.10.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Notably, the authors included 27 cancer types in their cohort, where the most common cancers were endometrial (n=49), gastric (n=24), cholangiocarcinoma (n=22), pancreatic (n=22) and small intestine (n=19). Overall, the studies above clearly suggest that MMR-D in solid tumors is a predictor of response to immune checkpoint inhibitor therapy. [...]the ORR and durable responses were also similar to experiences with immune checkpoint inhibitors in patients with MMR-D colorectal cancer. Markedly, a study investigating the impact of BRCA gene alterations in solid tumor reported BRCA mutations in non-BRCA associated cancers may not have any clinical implication (17) suggesting highly actionable molecular alterations may have a distinct impact (or potentially no impact) on different types of cancer. [...]prospective studies are needed to evaluate the predictor role of characterization of T-cell infiltrate on immune checkpoint inhibitor response/resistance in cancer patients with MMR-D tumors. |
---|---|
ISSN: | 1758-194X 1758-1958 |
DOI: | 10.2217/crc-2020-0020 |